| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
|
Product name |
FEvipiprant |
|
CAS No. |
872365-14-5 |
| Molecular Formula | C19H17F3N2O4S |
| Purity | 99% |
Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment. [(3)H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 ± 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2(PGD2). QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells. Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.
Fevipiprant is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of Setipiprant have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery.
|
Product name
|
CAS No.
|
|
β-Nicotinamide Mononucleotide (NMN)
|
1094-61-7
|
|
beta-Diphosphopyridine nucleotide (NAD)
|
53-84-9
|
|
Nicotinamide riboside chloride (NRC)
|
23111-00-4
|
|
Nicotinamide Ribose (NR)
|
1341-23-7
|
|
|
53-43
|
Extraction process:
){kind=link}